Wright Medical Group NV (NASDAQ:WMGI) SVP Barry J. Regan bought 10,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was acquired at an average price of $21.50 per share, for a total transaction of $215,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
NASDAQ:WMGI opened at $21.01 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.70 and a current ratio of 0.91. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of 230.78, a price-to-earnings-growth ratio of 8.54 and a beta of 0.69. Wright Medical Group NV has a 52 week low of $20.46 and a 52 week high of $32.86. The firm has a 50-day moving average price of $26.69 and a two-hundred day moving average price of $29.77.
Wright Medical Group (NASDAQ:WMGI) last posted its quarterly earnings data on Wednesday, August 7th. The medical device company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.01. The firm had revenue of $229.73 million during the quarter, compared to analyst estimates of $233.04 million. Wright Medical Group had a negative net margin of 14.65% and a positive return on equity of 1.37%. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.03) EPS. As a group, sell-side analysts forecast that Wright Medical Group NV will post 0.17 earnings per share for the current year.
WMGI has been the topic of a number of analyst reports. Oppenheimer lowered their target price on shares of Wright Medical Group from $34.00 to $29.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. BidaskClub upgraded shares of Wright Medical Group from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BMO Capital Markets lowered their target price on shares of Wright Medical Group from $36.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Wells Fargo & Co lowered shares of Wright Medical Group from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $28.00 to $23.00 in a research note on Monday. Finally, Royal Bank of Canada lowered shares of Wright Medical Group from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $34.00 to $24.00 in a research note on Thursday, August 8th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $31.38.
Wright Medical Group Company Profile
Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells upper and lower extremities, and biologics products in the United States, Europe, the Middle East, Africa, Canada, Asia, Australia, and Latin America. The company offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Wright Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wright Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.